Source link : https://www.newshealth.biz/health-news/molnupiravir-may-offer-modest-6-month-benefits-for-high-risk-covid-patients/
People with acute COVID-19 who took the antiviral drug molnupiravir (Lagevrio) reported modest improvements in symptoms, less time off from work or study, and less healthcare utilization at 6 months post-infection, a follow-up analysis of the prospective, open-label PANORAMIC trial suggested. Among patients who received molnupiravir 800 mg twice per day plus usual care for […]
Author : News Health
Publish date : 2024-09-11 18:48:43
Copyright for syndicated content belongs to the linked Source.